Clinical Scorecard: Exploring the Role of Autoantibodies in Sensory Disturbances Associated with Fibromyalgia

At a Glance

Key Highlights

• Autoantibodies (IgG) from fibromyalgia patients induce mechanical and cold hypersensitivity when transferred to mice, implicating immune mechanisms in pathophysiology.
• Large-diameter Aβ mechanoreceptors show sensitization with reduced mechanical thresholds and increased firing rates, contributing to sensory abnormalities.
• Microneurography recordings in patients reveal altered Aβ SA fibre responses to mechanical and cold stimuli, supporting translational findings.

Guideline-Based Recommendations

Diagnosis

• Consider assessment of sensory abnormalities including paraesthesia, dysaesthesia, and temperature sensitivity in fibromyalgia patients.
• Utilize patient-reported symptom questionnaires to correlate sensory disturbances with disease severity.
• Employ advanced neurophysiological techniques such as microneurography for detailed sensory nerve function evaluation where available.

Management

• Recognize the potential role of autoantibodies in fibromyalgia to guide future therapeutic strategies.
• Consider plasma exchange as a potential intervention to reduce circulating autoantibodies, noting preliminary evidence of symptom improvement.
• Current therapies remain largely ineffective; research into immune-targeted treatments is warranted.

Monitoring & Follow-up

• Monitor sensory symptom severity and temperature sensitivity as part of clinical evaluation.
• Track changes in patient-reported sensory disturbances to assess disease progression or treatment response.

Risks

• Sensory hypersensitivity may increase risk of discomfort and reduced quality of life.
• Limited understanding of long-term effects of autoantibody involvement necessitates cautious interpretation of emerging therapies.

Patient & Prescribing Data

Fibromyalgia patients exhibiting sensory hypersensitivities and autoantibody presence

Plasma exchange reducing >80% of circulating antibodies showed subjective symptom improvement in some patients; however, standard pharmacologic treatments remain largely ineffective.

Clinical Best Practices

• Integrate patient symptom reports with neurophysiological assessments to characterize sensory abnormalities.
• Consider the contribution of both small and large fibre dysfunction in fibromyalgia sensory symptoms.
• Support research participation to advance understanding of immune mechanisms and develop targeted therapies.

References

• Aβ low threshold mechanoreceptors contribute to sensory abnormalities in fibromyalgia by Israel et al.